Literature DB >> 2665849

Interleukin-1 stimulates proliferation of acute myeloblastic leukemia cells by induction of granulocyte-macrophage colony-stimulating factor release.

R Delwel1, C van Buitenen, M Salem, F Bot, S Gillis, K Kaushansky, B Altrock, B Löwenberg.   

Abstract

In this study, we further established the role of interleukin-1 (IL-1) alpha and IL-1 beta as regulators of proliferation of acute myeloid leukemia (AML) cells. IL-1 stimulated tritiated thymidine (3H-TdR) uptake of AML cells in 13 of 28 cases. Cytogenetic analysis confirmed the leukemic clonality of the IL-1-stimulated cells. Most likely, IL-1 exerted these stimulative effects directly on AML blast cells because IL-1 effectively induced 3H-TdR uptake of CD34-positive AML blasts (separated following cell sorting). Furthermore, adherent cell-depleted AML samples of three patients were more effectively stimulated than nondepleted AML fractions. Cluster and colony formation from adherent cell depleted AML samples could also be stimulated with IL-1, ie, in seven of ten cases analyzed. Subsequent experiments indicated that IL-1 stimulation depended on the release of GM-CSF because (1) induction of DNA synthesis of AML cells by IL-1 could be abrogated with antigranulocyte-macrophage colony-stimulating factor (GM-CSF) antibody, (2) conditioned media (CM) prepared from IL-1 stimulated AML blasts (adherent cell depleted) could stimulate the proliferation of purified normal bone marrow progenitors whereas supernatants from nonstimulated AML blasts did not, and (3) GM-CSF was demonstrated in IL-1/AML-CM with a specific radioimmunoassay, while GM-CSF was not detectable in nonstimulated supernatants. In one case of AML showing significant 3H-TdR uptake in the absence of CSFs, this spontaneous DNA synthesis was found to depend on autocrine IL-1 beta release as it could be suppressed with anti-IL-1 beta antibody or anti-GM-CSF. The blockade by anti-IL-1 beta could be overcome by the addition of high concentrations of IL-1 beta as well as GM-CSF. Thus, in this particular case, endogenously produced IL-1 beta had stimulated the release of GM-CSF which resulted in GM-CSF-dependent proliferation. The results indicate that GM-CSF production by AML blasts is often regulated by IL-1 rather than being constitutive.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2665849

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  The NLRP3 inflammasome in health and disease: the good, the bad and the ugly.

Authors:  P Menu; J E Vince
Journal:  Clin Exp Immunol       Date:  2011-07-15       Impact factor: 4.330

Review 2.  The case for extracellular Nm23-H1 as a driver of acute myeloid leukaemia (AML) progression.

Authors:  A Joshua Lilly; Farhat L Khanim; Christopher M Bunce
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-08-15       Impact factor: 3.000

Review 3.  Extracellular NME proteins: a player or a bystander?

Authors:  Patrizia Romani; Marilena Ignesti; Giuseppe Gargiulo; Tien Hsu; Valeria Cavaliere
Journal:  Lab Invest       Date:  2017-10-16       Impact factor: 5.662

4.  Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.

Authors:  Alyssa Carey; David K Edwards; Christopher A Eide; Laura Newell; Elie Traer; Bruno C Medeiros; Daniel A Pollyea; Michael W Deininger; Robert H Collins; Jeffrey W Tyner; Brian J Druker; Grover C Bagby; Shannon K McWeeney; Anupriya Agarwal
Journal:  Cell Rep       Date:  2017-03-28       Impact factor: 9.423

5.  IL-6 blockade reverses bone marrow failure induced by human acute myeloid leukemia.

Authors:  Tian Yi Zhang; Ritika Dutta; Brooks Benard; Feifei Zhao; Raymond Yin; Ravindra Majeti
Journal:  Sci Transl Med       Date:  2020-04-08       Impact factor: 17.956

Review 6.  Cytokine-mediated gene therapy for cancer.

Authors:  A R Miller; W H McBride; K Hunt; J S Economou
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

7.  GATA Factor-Dependent Positive-Feedback Circuit in Acute Myeloid Leukemia Cells.

Authors:  Koichi R Katsumura; Irene M Ong; Andrew W DeVilbiss; Rajendran Sanalkumar; Emery H Bresnick
Journal:  Cell Rep       Date:  2016-08-18       Impact factor: 9.423

8.  Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.

Authors:  Helena Ågerstam; Christine Karlsson; Nils Hansen; Carl Sandén; Maria Askmyr; Sofia von Palffy; Carl Högberg; Marianne Rissler; Mark Wunderlich; Gunnar Juliusson; Johan Richter; Kjell Sjöström; Ravi Bhatia; James C Mulloy; Marcus Järås; Thoas Fioretos
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-10       Impact factor: 11.205

9.  Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia.

Authors:  Stephen E Kurtz; Christopher A Eide; Andy Kaempf; Nicola Long; Daniel Bottomly; Olga Nikolova; Brian J Druker; Shannon K McWeeney; Bill H Chang; Jeffrey W Tyner; Anupriya Agarwal
Journal:  Blood Adv       Date:  2022-05-24

10.  The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis

Authors:  Bauke De Boer; Sofia Sheveleva; Katja Apelt; Edo Vellenga; André B Mulder; Gerwin Huls; Jan Jacob Schuringa
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.